Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07581184 · ClinicalTrials.gov registry record · Phase 1
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by Aktis Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 138
- Enrollment target
NCT07581184 is a Phase 1 study that is actively recruiting participants, run by Aktis Oncology. The registered enrollment target is 138 participants.
The verdict
NCT07581184, a Phase 1 study, is actively recruiting participants, sponsored by Aktis Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 138 participants
- Enrollment target
Study Summary
This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac-AKY-2519 in participants with metastatic castration-resistant prostate cancer (mCRPC) with and without prior exposure to 177Lu-PSMA-617 (PLUVICTO™).
Interventions
- DRUG [225Ac]Ac-AKY-2519 (therapeutic)
- DRUG [64Cu]Cu-AKY-2519 (imaging)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2026-07 |
| Est. Completion | 2032-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07581184
The ClinicalTrials.gov registry entry for NCT07581184 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aktis Oncology, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which [225Ac]Ac-AKY-2519 (therapeutic) is the first listed.
NCT07581184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07581184 about?
NCT07581184 is a clinical study titled "A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer". This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac-AKY-2519 in participants with metastatic castration-resistan...
What is the current status of trial NCT07581184?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 138 participants. The study started on 2026-07. Estimated completion is 2032-06.
What interventions are being tested in trial NCT07581184?
The interventions under investigation include: [225Ac]Ac-AKY-2519 (therapeutic) (DRUG), [64Cu]Cu-AKY-2519 (imaging) (DRUG).
Who is sponsoring clinical trial NCT07581184?
This trial is sponsored by Aktis Oncology, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.